Commission signs vaccine contract with AstraZeneca

The first contract the Commission has negotiated on behalf of the EU Member States with a pharmaceutical company enters today into force following the formal signature between AstraZeneca and the Commission, the EU press service reported. The contract will allow the purchase of a vaccine against Covid-19 for all the Member States.

Through the contract, all Member States will be able to purchase 300 million doses of the AstraZeneca vaccine, with an option for further 100 million doses, to be distributed on a population-based pro-rata basis. The Commission continues discussing similar agreements with other vaccine manufacturers and has already concluded successful exploratory talks with Sanofi-GSK, Johnson & Johnson, CureVac and Moderna.

“The Commission is working non-stop to provide EU citizens with a safe and effective vaccine against Covid-19 as quickly as possible. The entry into force of the contract with AstraZeneca is an important step forward in this respect,” EC President Ursula von der Leyen said. “Our negotiations have now delivered clear results: a first contract signed delivering on our commitment to ensure a diversified vaccine portfolio to protect the public health of our citizens,” Health Commissioner Stella Kyriakides added.

AstraZeneca and the University of Oxford joined forces to develop and distribute the University's potential recombinant adenovirus vaccine aimed at preventing Covid-19 infection. AstraZeneca's vaccine candidate is already in large-scale Phase II/III Clinical Trials after promising results in Phase I/II concerning safety and immunogenicity.

Similar articles